Change to the Executive Board of Carl Zeiss AG for the Medical Technology segment

• Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will become the new Executive Board Member of Carl Zeiss AG responsible for the Medical Technology segment and the new CEO of the publicly listed Carl Zeiss Meditec AG.
• She will succeed Andreas Pecher, who, in addition to his primary role as President and CEO of Carl Zeiss AG, has served as CEO of Carl Zeiss Meditec AG on an interim basis since January 1, 2026.
• The exact start date is subject to current negotiations and will be communicated at a later time.

Jena/Oberkochen, Germany | May 22, 2026 | ZEISS Group

The Supervisory Board of Carl Zeiss AG has appointed Bronwyn Brophy O’Connor as the new Executive Board Member of Carl Zeiss AG responsible for the Medical Technology segment. At the same time, the Supervisory Board of the publicly listed Carl Zeiss Meditec AG has appointed her to its Management Board as CEO. Bronwyn Brophy O’Connor is currently CEO of the Vitrolife Group, which is headquartered in Gothenburg and listed on the NASDAQ Stockholm in Sweden. She previously held senior positions at multinational medical technology companies, such as Thermo Fisher Scientific, Medtronic, and Johnson & Johnson, and worked in the U.K., Ireland, Switzerland, Spain, and the U.S., among other countries. Her responsibilities have included strategy development, turnarounds, geographic expansion into American and Asian markets, mergers and acquisitions, as well as research and development programs, such as for the diagnosis of autoimmune diseases and the adoption of innovative therapies. In these roles, she had financial responsibility for up to eight billion euros.

This appointment concludes the selection process to fill the position of CEO of Carl Zeiss Meditec AG on a long-term basis. The President and CEO of Carl Zeiss AG, Andreas Pecher, took on this position on an interim basis in January 2026. Bronwyn Brophy O’Connor will take up her role at the ZEISS Medical Technology segment as soon as possible. The exact start date is subject to current negotiations and will be communicated at a later time. Until then, Andreas Pecher will continue to act as interim CEO of Carl Zeiss Meditec AG.

“With Bronwyn Brophy O’Connor, we are pleased to have found a successor who has excelled internationally. She has over 25 years of professional experience in medical technology and life sciences and, with her exceptional capabilities, will play a key role in shaping the ongoing realignment of ZEISS Medical Technology,” said Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG. “We wish her a great start and all the best for her new position at ZEISS.”

Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, added, “We would like to thank Andreas Pecher for his outstanding commitment and excellent work in his temporary additional role as interim head of the segment and CEO of Carl Zeiss Meditec AG. In a short time, Andreas Pecher laid the critical groundwork for the future success of ZEISS Medical Technology.”

Andreas Pecher, President and CEO of Carl Zeiss AG, said, “We are pleased that we have found a proven expert in Bronwyn Brophy O’Connor with her many years of experience in medical technology, which is a strategically important market for ZEISS. She will bring important momentum to Carl Zeiss Meditec AG and the ZEISS Group. I would like to thank our team at the ZEISS Medical Technology segment for their trust and strong commitment in the past months, and I am looking forward to once again focusing exclusively on my role as President and CEO of the ZEISS Group as soon as possible.”

The Executive Board of Carl Zeiss AG will consist of the following members: Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).

The Management Board of Carl Zeiss Meditec AG will consist of Bronwyn Brophy O’Connor (CEO) and Justus Wehmer (CFO).

Bronwyn Brophy O’Connor studied at Dublin City University in Ireland. After earning a bachelor’s degree in International Marketing and Languages (Spanish and French), she completed her Master of Business Administration in 2002. She started her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending her career there as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. Bronwyn then joined Covidien, which was later acquired by Medtronic to form the largest medtech company globally. From 2013 until 2018, she first served as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, Bronwyn joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, Bronwyn Brophy O’Connor has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden.

Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned a Master of Business Administration (MBA) at the Kellogg School of Management as well as a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas, USA, in 1998. After completing his MBA in 2005, Andreas Pecher worked as a project manager at McKinsey & Company in Germany. Starting in 2010, he headed the Strategy and Business Development department at the solar company Renewable Energy Corporation in Oslo, Norway, and Munich, Germany. In 2013, Andreas Pecher joined the ZEISS Semiconductor Manufacturing Technology (SMT) segment as Head of Strategic Business Development in Oberkochen, Germany. In 2015, he became Head of the Semiconductor Mask Solutions strategic business unit (SMS SBU) and, starting in 2017, headed the Semiconductor Manufacturing Optics strategic business unit. In 2022, Andreas Pecher became Head of the ZEISS SMT segment and was simultaneously appointed a Member of the Executive Board of Carl Zeiss AG. He was named President and CEO of Carl Zeiss AG effective April 1, 2025. In this role, he also took on the interim position as CEO of the publicly listed Carl Zeiss Meditec AG on January 1, 2026, becoming Head of the Medical Technology segment.